MedTrace Logo

The Effect of Triflusal on Peripheral Microcirculation Dysfunction

NCT01612273 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2014-03-05

No results posted yet for this study

Summary

To explore the efficacy of triflusal in patients with symptomatic peripheral microcirculation dysfunction. Triflusal is a salicylate compound approved in several countries as antithrombotic agent and it additionally has vasodilatory effect. The hypothesis is to explore if there is a improvement of peripheral microcirculation by triflusal.

Conditions

  • Vasospastic Syndrome

Interventions

DRUG

Triflusal

Dose: 300mg bid, Mode of administration: oral, Duration: from randomization to 6 week, crossover-design.

DRUG

Aspirin

Dose: 150mg bid, Mode of administration: oral, from randomization to 6weeks, crossover-design.

Sponsors & Collaborators

  • Yonsei University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2013-01-31
Completion
2013-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01612273 on ClinicalTrials.gov